Detalhe da pesquisa
1.
Triple-negative breast tumors are dependent on mutant p53 for growth and survival.
Proc Natl Acad Sci U S A
; 120(34): e2308807120, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37579145
2.
Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice.
Hepatology
; 63(3): 1000-12, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26637970
3.
Molecular mechanisms of oncogene-induced inflammation and inflammation-sustained oncogene activation in gastrointestinal tumors: an under-appreciated symbiotic relationship.
Biochim Biophys Acta
; 1846(1): 152-60, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821201
4.
Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30.
J Immunol
; 188(8): 3709-15, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22407920
5.
Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo.
Sci Adv
; 10(7): eadk1835, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354236
6.
Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury.
Hepatology
; 55(4): 1204-14, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22105582
7.
The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-κB1, STAT3, and CD40/CD154.
Cell Commun Signal
; 11: 95, 2013 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24330710
8.
Intricacies for posttranslational tumor-targeted cytokine gene therapy.
Mediators Inflamm
; 2013: 378971, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24369443
9.
p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Cancer Res Commun
; 3(12): 2640-2652, 2023 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38047594
10.
Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy.
Mol Ther
; 19(8): 1468-77, 2011 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21386825
11.
A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53.
PLoS One
; 13(3): e0193485, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29494633
12.
IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin.
Oncotarget
; 7(47): 77138-77151, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27738312
13.
Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.
Clin Cancer Res
; 22(15): 3876-83, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26979394
14.
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
J Natl Cancer Inst
; 107(8)2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25971300
15.
Universal marker and detection tool for human sarcoma circulating tumor cells.
Cancer Res
; 74(6): 1645-50, 2014 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24448245
16.
WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells.
PLoS One
; 6(4): e19072, 2011 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21559505
17.
Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance.
Cancer Res
; 69(13): 5505-13, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19549909